Riskpilot← Back to searchSign inGet full accessLife Science Legal ApS
APSActiveCVR 30738276Stærmosevej 12Research and experimental development on natural sciences and engineering · NACE 7210Est. 20072 employees
Revenue 2025
DKK 3,8M
+341% vs 2024
EBITDA margin
47.7%
+320% vs 2024
Equity ratio
73.4%
Financial strength
Net profit 2025
DKK 1,8M
+53% vs 2024
| Revenue | DKK 3,8M | +341% |
| EBITDA | DKK 1,8M | +320% |
| Net profit | DKK 1,8M | +53% |
| Total assets | DKK 3M | +200% |
| Equity | DKK 2,2M | +264% |
| Employees | 2 | — |
Legal name
Life Science Legal ApS
CVR number
30738276
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. august 2007
Share capital
DKK 224.977
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at udføre konsulentydelser og enhver aktivitet relateret til life science branchen (herunder deltagelse i lægemiddeludvikling) der efter direktionens skøn står i forbindelse hermed.
Address
Stærmosevej 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -624 | 565 | 2.289 | 854 | 3.764 |
| Staff expenses | -494 | -1.971 | -1.793 | -176 | -1.967 |
| EBITDA | -1.118 | -1.406 | 496 | 428 | 1.797 |
| Depreciation & amort. | -0 | -0 | -14.919 | -0 | -0 |
| EBIT | -1.118 | -1.406 | -14.423 | 428 | 1.797 |
| Net financials | -205 | -255 | -176 | 747 | 1 |
| Profit before tax | -1.323 | -1.661 | -14.599 | 1.175 | 1.797 |
| Tax | -563 | -604 | -1.299 | -0 | -0 |
| Net profit | -760 | -1.057 | -13.300 | 1.175 | 1.797 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 19.546 | 19.352 | 1.728 | 1.014 | 3.041 |
| Equity | 14.039 | 12.982 | -318 | 614 | 2.233 |
| Long-term debt | 2.424 | 2.826 | 1.262 | 0 | 0 |
| Short-term debt | 2.395 | 2.639 | 784 | 400 | 808 |
| Total debt | 4.819 | 5.465 | 2.046 | 400 | 808 |
EBITDA margin
47.7%
This company
15.8%
Market median
+202% vs market
20212025
Equity ratio
73.4%
This company
38.2%
Market median
+92% vs market
20212025
Return on equity
80.5%
This company
18.4%
Market median
+338% vs market
20212025
Net profit margin
47.8%
This company
8.1%
Market median
+490% vs market
20212025
Asset turnover
1.24×
This company
1.12×
Market median
+11% vs market
20212025
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NP Management | Management | 2024 |
| Former (3) | ||
SB Management | Management | 2010 – 2015 |
IS Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
GM Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (11) | ||
| Chairman | 2007 – 2008 | |
| Board of Directors | 2015 – 2015 | |
| Board of Directors | 2007 – 2018 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2020 – 2023 | |
| Board of Directors | 2007 – 2016 | |
| Board of Directors | 2015 – 2021 | |
| Board of Directors | 2010 – 2015 | |
| Chairman | 2015 – 2019 | |
| Chairman | 2023 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.67–89.99% | 66.67–89.99% | 2025 | |
| Company | 25–33.32% | 25–33.32% | 2025 | |
| Company | 20–24.99% | 20–24.99% | 2007 | |
| Company | 15–19.99% | 15–19.99% | 2020 | |
| Company | 15–19.99% | 15–19.99% | 2020 | |
| Company | 5–9.99% | 5–9.99% | 2020 | |
| Individual | 5–9.99% | 5–9.99% | 2020 | |
| Company | 5–9.99% | 5–9.99% | 2020 | |
| Individual | 10–14.99% | 10–14.99% | 2010 | |
| Individual | 10–14.99% | 10–14.99% | 2014 | |
| Individual | 10–14.99% | 10–14.99% | 2020 | |
| Individual | 15–19.99% | 15–19.99% | 2021 | |
| Company | 5–9.99% | 5–9.99% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Life Science Legal ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Niels Peter Løvgren | Management | 0 companies |
| Shervin Bahrami | Management | 0 companies |
| Ingelise Saunders | Chief Executive Officer | 0 companies |
| Gert Mads Bolwig | Chief Executive Officer | 0 companies |
| Jørn Renz Enggaard | Chairman | 0 companies |
| Lars Henning Stigel | Board of Directors | 0 companies |
| Finn Skou Pedersen | Board of Directors | 0 companies |
| Stephan Christgau | Board of Directors | 0 companies |
| Hans van Eenennaam | Board of Directors | 0 companies |
| Pieter Jeroen Bakker | Board of Directors | 0 companies |
| Mogens Ryttergård Duch | Board of Directors | 0 companies |
| Alejandra Maria Cristina Bonifacini Mørk | Board of Directors | 0 companies |
| Jørn Frederik Falch | Board of Directors | 0 companies |
| Lars Jørgen Østergaard | Chairman | 0 companies |
| Claus Hansen | Chairman | 0 companies |